Chang’an II Decoction (肠安 II 号方)-Containing Serum Ameliorates Tumor Necrosis Factor-α-Induced Intestinal Epithelial Barrier Dysfunction via MLCK-MLC Signaling Pathway in Rats

  • Ting Chen
  • Xiao-lan Yin
  • Nan Kang
  • Xiao-ge Wang
  • Bao-shuang Li
  • Hai-jie Ji
  • Yin-qiang Zhang
  • Li-qun Bian
  • Bei-hua Zhang
  • Feng-yun Wang
  • Xu-dong TangEmail author
Original Article



To investigate the effect of Chang’an II Decoction (肠安 II 号方))-containing serum on intestinal epithelial barrier dysfunction in rats.


Tumor necrosis factor (TNF)-α-induced injury of Caco-2 monolayers were established as an inflammatory model of human intestinal epithelium. Caco-2 monolayers were treated with blank serum and Chang’an II Decoction-containing serum that obtained from the rats which were treated with distilled water and Chang’an II Decoction intragastrically at doses of 0.49, 0.98, 1.96 g/(kg·d) for 1 week, respectively. After preparation of containing serum, cells were divided into the normal group, the model group, the Chang’an II-H, M, and L groups (treated with 30 ng/mL TNF-α and medium plus 10% high, middle-, and low-doses Chang’an II serum, respectively). Epithelial barrier function was assessed by transepithelial electrical resistance (TER) and permeability of fluorescein isothiocyanate (FITC)-labeled dextran. Transmission electron microscopy was used to observe the ultrastructure of tight junctions (TJs). Immunofluorescence of zonula occludens-1 (ZO-1), claudin-1 and nuclear transcription factor-kappa p65 (NF-κ Bp65) were measured to determine the protein distribution. The mRNA expression of myosin light chain kinase (MLCK) was measured by real-time polymerase chain reaction. The expression levels of MLCK, myosin light chain (MLC) and p-MLC were determined by Western blot.


Chang’an II Decoction-containing serum significantly attenuated the TER and paracellular permeability induced by TNF-α. It alleviated TNF-α-induced morphological alterations in TJ proteins. The increases in MLCK mRNA and MLCK, MLC and p-MLC protein expressions induced by TNF-α were significantly inhibited in the Chang’an II-H group. Additionally, Chang’an II Decoction significantly attenuated translocation of NF-κ Bp65 into the nucleus.


High-dose Chang’an II-containing serum attenuates TNF-α-induced intestinal barrier dysfunction. The underlying mechanism may be involved in inhibiting the MLCK-MLC phosphorylation signaling pathway mediated by NF-κ Bp65.


myosin light chain kinase-myosin light chain signaling pathway intestinal epithelial cells tight junction tumor necrosis factor-α Chang’an II Decoction drug-containing serum 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


Author Contributions

Tang XD, Wang FY and Chen T designed the study, Chen T carried out the experiments and draft of the manuscript, Yin XL co-participated in draft and publication of the paper. Kang N participated in the experimental design and Wang XG coordinated the experiments. Ji HJ, Bian LQ and Zhang BH involved in discussion of experiment. All authors read and approved the final manuscript.

Conflict of Interest

The authors declare no financial or commercial conflict of interest.

Supplementary material

11655_2019_3034_MOESM1_ESM.pdf (155 kb)
Appendix 1. Analysis of the Chemical Constituents of Chang’an II Decoction by High-Performance Liquid Chromatography.


  1. 1.
    Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology 2016;150:1393–1407.CrossRefGoogle Scholar
  2. 2.
    Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014;6:71–80.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 2012; 47:1177–1185.PubMedCrossRefGoogle Scholar
  4. 4.
    Bercik P, Wang L, Verdu EF, Mao YK, Blennerhassett P, Khan WI, et al. Visceral hyperalgesia and Intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 2004;127:179–187.PubMedCrossRefGoogle Scholar
  5. 5.
    Ledochowski M, Propst T, Fuchs D. The role of psychological and biological factors in post infective gut dysfunction. Gut 2000;46:140–141.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Kimball ES, Palmer JM, D’Andrea MR, Hornby PJ, Wade PR. Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice. Amer J Physiol Gastrointest Liver Phys 2005;288:G1266–G1273.CrossRefGoogle Scholar
  7. 7.
    Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015;12:36–49.PubMedCrossRefGoogle Scholar
  8. 8.
    Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nature Review Immunol 2014;14:141–153.CrossRefGoogle Scholar
  9. 9.
    Bertiaux-Vandaele N, Youmba SB, BeLmonte L, Lecleire S, Antonietti M, Gourcerol G, et al. The expression and the cellular distribution of the tight junction proteins are altered in Irritable bowel syndrome patients with differences according to the disease subtype. Ame J Gastroenterol 2011;106:2165–2173.CrossRefGoogle Scholar
  10. 10.
    Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, et al. Impaired Intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009;58:196–201.PubMedCrossRefGoogle Scholar
  11. 11.
    Bashashati M, Rezaei N, Andrews CN, Chen CQ, Daryani NE, Sharkey KA, et al. Cytokines and irritable bowel syndrome: where do we stand? Cytokine 2012;57:201–209.PubMedCrossRefGoogle Scholar
  12. 12.
    Darkoh C, Comer L, Zewdie G, HaroLd S, Snyder N, DuPont HL. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS One 2014;9:1–8.CrossRefGoogle Scholar
  13. 13.
    Clark IA. How TNF was recognized as a key mechanism of disease. Cytok Growth Factor Rev 2007;18:335–343.CrossRefGoogle Scholar
  14. 14.
    Ma TY, Boivin MA, Ye D, Pedram A, Said HM. Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005;288:G422–G430.PubMedCrossRefGoogle Scholar
  15. 15.
    Hecht G, Pestic L, Nikcevic G, Koutsouris A, Tripuraneni J, Lorimer DD, et al. Expression of the catalytic domain of myosin light chain kinase increases paracellular permeability. Am J Physiol 1996;271:C1678–C1684.PubMedCrossRefGoogle Scholar
  16. 16.
    Ivanov AI, McCall IC, Parkos CA, Nusrat A. Role for actin filament turnover and a myosin II motor in cytoskeleton-driven disassembly of the epithelial apical junctional complex. Mol Biol Cell 2004;15:2639–2651.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Ma TY, Tran D, Hoa N, Nguyen D, Merryfield M, Tarnawski A. Mechanism of extracellular calcium regulation of Intestinal epithelial tight junction permeability: role of cytoskeletal involvement. Microsc Res Tech 2000;51:156–168.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Shen L, Black ED, Witkowski ED, Lencer WI, Guerriero V, Schneeberger EE, et al. Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci 2006;119:2095–2106.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Cao M, Wang P, Sun CH, He W, Wang FJ. Amelioration of IFN-γ and TNF-α-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway. PLoS One 2013;8:1–9.Google Scholar
  20. 20.
    Liu H, Wang P, Cao M, Li M, Wang F. Protective role of oligomycin against intestinal epithelial barrier dysfunction caused by IFN-γ and TNF-α. Cell Physiol Biochem 2012;29:799–808.PubMedCrossRefGoogle Scholar
  21. 21.
    Bian Z, Wu T, Liu L, Miao J, Wong H, Song L, et al. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med 2006;12:401–407.PubMedCrossRefGoogle Scholar
  22. 22.
    Wang CW, Shi J, Ke F. Meta-analysis of the effectiveness of Tong Xie Yao Fang in treating irritable bowel syndrome. World Chin J Digest (Chin) 2007;15:1934–1939.Google Scholar
  23. 23.
    Wang FY, Su M, Zheng YQ, Wang XG, Kang N, Chen T, et al. Herbal prescription Chang’an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome. Acta Pharmacol Sin 2015;36:708–715.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006;169:1901–1909.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Zhang K, Hornef MW, Dupont A. The intestinal epithelium as guardian of gut barrier integrity. Cell Microbiol 2015;17:1561–1569.PubMedCrossRefGoogle Scholar
  26. 26.
    Watson AJ, Hughes KR. TNF-α -induced intestinal epithelial cell shedding: implications for intestinal barrier function. Ann N Y Acad Sci 2012;1258:1–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Noth R, Stüber E, Häsler R. Anti-TNF-α antibodies improve intestinal barrier function in Crohn’s disease. J Crohns Colitis 2012;6:464–469.PubMedCrossRefGoogle Scholar
  28. 28.
    Forster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 2008;130:55–70.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Matter K, Balda MS. Signaling to and from tight junctions. Nat Rev Mol Cell Biol 2003;4:225–236.PubMedCrossRefGoogle Scholar
  30. 30.
    Steed E, Balda MS, Matter K. Dynamics and functions of tight junctions. Trends Cell Biol 2010;20:142–149.PubMedCrossRefGoogle Scholar
  31. 31.
    Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013;70:631–659.PubMedCrossRefGoogle Scholar
  32. 32.
    Gu L, Li N, Li Q, Zhang Q, Wang C, Zhu W, et al. The effect of berberine in vitro on tight junctions in human Caco-2 intestinal epithelial cells. Fitoterapia 2009;80:241–248.PubMedCrossRefGoogle Scholar
  33. 33.
    Grozdanovic MM, Čavić M, Nešić A, Andjelković U, Akbari P, Smit JJ, et al. Kiwifruit cysteine protease actinidin compromises the intestinal barrier by disrupting tight junctions. Biochim Biophys Acta 2016;1860:516–526.PubMedCrossRefGoogle Scholar
  34. 34.
    Jeong CH, Seok JS, Petriello MC, Han SG. Arsenic downregulates tight junction claudin proteins through p38 and NF-κ B in intestinal epithelial cell line, HT-29. Toxicology 2017;379:31–39.PubMedCrossRefGoogle Scholar
  35. 35.
    Vila L, García-Rodríguez A, Cortés C, Marcos R, Hernández A. Assessing the effects of silver nanoparticles on monolayers of differentiated Caco-2 cells, as a model of intestinal barrier. Food Chem Toxicol 2018;116:1–10.PubMedCrossRefGoogle Scholar
  36. 36.
    Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166:409–419.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 2004;286:G367–G376.PubMedCrossRefGoogle Scholar
  38. 38.
    Cunningham KE, Turner JR. Myosin light chain kinase: pulling the strings of epithelial tight junction function. Ann N Y Acad Sci 2012;1258:34–42.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2006;290:G496–G504.PubMedCrossRefGoogle Scholar
  40. 40.
    Widera D, Mikenberg I, Elvers M, Kaltschmidt C, Kaltschmidt B. Tumor necrosis factor alpha triggers proliferation of adult neural stem cells via IKK/NF-kappa B signaling. BMC Neurosci 2006;7:64–82.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Al-Sadi R, Guo S, Ye D, Rawat M, Ma TY. TNF-α modulation of intestinal tight junction permeability is mediated by NIK/IKK-α axis activation of the canonical NF-κB pathway. Am J Pathol 2016;186:1151–1165.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Ting Chen
    • 1
  • Xiao-lan Yin
    • 2
  • Nan Kang
    • 3
  • Xiao-ge Wang
    • 4
  • Bao-shuang Li
    • 1
  • Hai-jie Ji
    • 1
  • Yin-qiang Zhang
    • 5
  • Li-qun Bian
    • 1
  • Bei-hua Zhang
    • 1
  • Feng-yun Wang
    • 1
  • Xu-dong Tang
    • 1
    Email author
  1. 1.Department of Gastroenterology, Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijingChina
  2. 2.Graduate School of China Academy of Chinese Medical SciencesBeijingChina
  3. 3.Department of Internal MedicineJining Medical College Affiliated Hospital, JiningShandong ProvinceChina
  4. 4.Department of GastroenterologyHenan University of Chinese Medicine Affiliated HospitalZhengzhouChina
  5. 5.Department of Liver Diseases, Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijingChina

Personalised recommendations